Studies on muramidase in hematologic disorders. I. Serum Muramidase and Serum Lactic Dehydrogenase in Leukemia

J. Levi,Joan B. Speden Nzimlt,P. Vincent,F. Gunz
DOI: https://doi.org/10.1002/1097-0142(197304)31:4<939::AID-CNCR2820310427>3.0.CO;2-O
IF: 6.9209
1973-04-01
Cancer
Abstract:Estimations of serum muramidase (S.M.) and lactic acid dehydrogenase (L.D.H.) were made at the time of presentation in 79 adults with various forms of leukemia and compared with a number of other biochemical and hematologic parameters. In 35 patients, serial studies of these enzymes were also carried out. Initial S.M. levels, but not L.D.H. levels, were found to be of assistance in the diagnosis of the type of leukemia present. In patients with acute myeloblastic leukemia (A.M.L.), high pretreatment levels of S.M. tended to have a favorable prognosis. There was good correlation between initial S.M. and L.D.H., serum uric acid, total white cell count, absolute blast and granulocyte counts when all leukemias were taken together. However, this was not a consistent finding in analyses of the individual types of leukemia. In serial studies, S.M., and to a lesser extent L.D.H., paralleled the hematologic fluctuations in a high proportion of cases. When remissions were complete, S.M. and L.D.H. values returned to normal and remained so until relapse supervened. From these studies, we conclude that S.M. and L.D.H. are useful ancillary aids to the methods commonly employed for differentiating the types of leukemia, and that estimations of these enzymes also have some value in assessing the progress and prognosis of the disease.
What problem does this paper attempt to address?